Salivary and Serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome

Oral Health and Preventive Dentistry

Volumn 11, Issue 3, 2013, Pages 229-234

  Mumcu, Gonca ^a   Biçakçigil, Müge ^b   Yilmaz, Neslihan ^a   Ozay, Hale ^c   Karaçayli, ümit ^d   Cimilli, Hale ^a   Yavuz, Sule ^e  

^a MARMARA UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

^c MINISTRY OF HEALTH   (Turkey)

^d GULHANE SCHOOL OF MEDICINE   (Turkey)

^e ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

BAFF level; Hydroxychloroquine; Sj gren's syndrome

Indexed keywords

B CELL ACTIVATING FACTOR; ENZYME INHIBITOR; HYDROXYCHLOROQUINE;

ADULT; ARTICLE; BLOOD; CHEMISTRY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SALIVA; SECRETION (PROCESS); SECRETION RATE; SICKNESS IMPACT PROFILE; SJOEGREN SYNDROME; TURKEY (REPUBLIC);

ADULT; B-CELL ACTIVATING FACTOR; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SALIVA; SECRETORY RATE; SICKNESS IMPACT PROFILE; SJOGREN'S SYNDROME; STATISTICS, NONPARAMETRIC; TURKEY;

EID: 84887358612     PISSN: 16021622     EISSN: 17579996     Source Type: Journal    
DOI: 10.3290/j.ohpd.a30172     Document Type: Article

References (30)

1. Cankaya H, Alpoz E, Karabulut G, Guneri P, Boyacioglu H, Kabasakal Y. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:62-67.
2. Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum 2007;56:1134-1144.
3. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjögren's syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005;44:449-455.
4. Delaleu N, Jonsson R, Koller MM. Sjögren's syndrome. Eur J Oral Sci 2005;113:101-113.
5. Delaleu N, Jonsson MV, Appel S, Jonsson R. New concepts in the pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am 2008;34:833-845.
6. Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009;5: 433-441.
7. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5(suppl 1):S31-36.
8. Gotoh S, Watanabe Y, Fujibayashi T. Validity of stimulated whole saliva collection as a sialometric evaluation for diagnosing Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:299-302.
9. Jonsson MV, Szodoray P, Jellestad S, Jonsson R, Skarstein K. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren's syndrome. J Clin Immunol 2005;25: 189-201.
10. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW. Hydroxychloroquine treatment for primary Sjögren's syndrome; a two year, double blind cross over trial. Ann Rheum Dis 1993;52:60-64.
11. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-703.
12. Lied GA, Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 2011;73:1-7.
13. McGrath C, Comfort MB, Lo EC, Luo Y. Patient-centred outcome measures in oral surgery: validity and sensitivity. Br J Oral Maxillofac Surg 2003;41:43-47.
14. McInnes IB, Jacobs JWG, Woodburn J, van Laar JM. Treatment of rheumatoid arthritis. EULAR online course on rheumatic diseases 2009;6:1-29.
15. Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U, Yavuz S, Sur H, Atalay T, Direskeneli H. Oral health related quality of life is affected by disease activity in Behcet's disease. Oral Dis 2006;12:145-151.
16. Ota M, Duong BH, Torkamani A, Doyle CM, Gavin AL, Ota T, Nemazee D. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol 2010;185:4128-4136.
17. Pers JO, d'Arbonneau F, Devauchelle-Pensec V, Saraux A, Pennec YL, Youinou P. Is periodontal disease mediated by salivary BAFF in Sjögren's syndrome? Arthritis Rheum 2005;52:2411-2414.
18. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-1477.
19. Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjögren's syndrome. Rheumatology (Oxford). 2009;48:796-799.
20. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, Gestermann N, Proust A, Lambotte O, Mariette X. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 2007;66:790-797.
21. Slade GD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol 1997;25:284-290.
22. Stewart CM, Berg KM, Cha S, Reeves WH. Salivary dysfunction and quality of life in Sjögren's syndrome: a critical oralsystemic connection. J Am Dent Assoc 2008;139:291-299; quiz 358-299.
23. Sutherland AP, Mackay F, Mackay CR. Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 2006;112:774-786.
24. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T. Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. Cytokine 2008;44:44-48.
25. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 1999;58:253-256.
26. Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF. Autoimmun Rev 2010;9:604-608.
27. Venables PJ. Sjögren's syndrome. Best Pract Res Clin Rheumatol 2004;18:313-329.
28. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
29. Yavuz S, Asfuroglu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjögren's syndrome. Rheumatol Int 2011;31:1045-1049.
30. Zhao LD, Li Y, Smith MF, Jr., Wang JS, Zhang W, Tang FL, Tian XP, Wang HY, Zhang FC, Ba DN, He W, Zhang X. Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients. Lupus 2010;19: 1534-1549.